The shares of Chesapeake Energy Corporation (NYSE:CHK) has been pegged with a rating of In-line by Imperial Capital in its latest research note that was published on January 10th, 2019. The research company has also assigned a $3 price target. Imperial Capital wasn’t the only research firm that published a report of Chesapeake Energy Corporation, with other equities research analysts also giving their opinion on the stock. BofA/Merrill advised investors in its research note published on January 4th, 2019, to Underperform the CHK stock. The stock had earned Underweight rating from CapitalOne when it published its report on December 20th, 2018. The stock was given Underweight rating by JP Morgan in its report released on December 7th, 2018. MKM Partners was of a view that CHK is Neutral in its latest report on December 6th, 2018 while giving it a price target of $3. Citigroup thinks that CHK is worth Neutral rating. This was contained in the firm’s report on November 12th, 2018.
Amongst the analysts that rated the stock, 3 have recommended investors to sell it, 11 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $3.06. The price of the stock the last time has raised by 40.35% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 37.13.
The shares of the company added by 0.42% during the trading session on Monday, reaching a low of $2.345 while ending the day at $2.40. During the trading session, a total of 41.6 million shares were traded which represents a 4.43% incline from the average session volume which is 43.53M shares. CHK had ended its last session trading at 2.39. Chesapeake Energy Corporation currently has a market cap of $2.27B, while its P/E ratio stands at 3.89, while its P/E earnings growth sits at 0.23, with a beta of 2.47. CHK 52-week low price stands at $1.71 while its 52-week high price is $5.60.
The company in its last quarterly report recorded $0.19 earnings per share which is above the $0.15 predicted by most analysts. The Chesapeake Energy Corporation generated $2,418.00 million in revenue during the last quarter, which is slightly higher than the $2,345.90 million predicted by analysts. In the second quarter last year, the firm recorded $0.15 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 21.05%. Chesapeake Energy Corporation has the potential to record 0.62 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Credit Suisse published a research note on January 31st, 2019 where it informed investors and clients that Pfizer Inc. (NYSE:PFE) is now rated as Outperform. BofA/Merrill also rated PFE as Downgrade on January 4th, 2019, with its price target of $17 suggesting that PFE could surge by 6.42% from its current share price. Even though the stock has been trading at $42.23/share, analysts expect it to surge higher by -1.30% to reach $44.54/share. It started the day trading at $42.31 and traded between $41.51 and $41.68 throughout the trading session.
A look at its technical shows that PFE’s 50-day SMA is 42.85 while its 200-day SMA stands at 40.74. The stock has a high of $46.47 for the year while the low is $33.20. The company’s P/E ratio currently sits at 22.46, while the P/B ratio is 3.43. The company’s average trading volume currently stands at 26.24M shares, which means that the short-interest ratio is just 1.79 days. Over the past seven days, the company moved, with its shift of -1.79%. Looking further, the stock has dropped -6.13% over the past 90 days while it gained 1.66% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more PFE shares, increasing its portfolio by +1.56% during the last quarter. This move now sees The Vanguard Group Inc purchasing 6,668,599 shares in the last quarter, thus it now holds 433,207,000 shares of PFE, with a total valuation of $18,909,485,550. SSgA Funds Management Inc meanwhile bought more PFE shares in the recently filed quarter, changing its stake to $12,861,441,596 worth of shares. BlackRock Fund Advisors followed the path by increasing its PFE portfolio by +0.34% in the quarter. This means that BlackRock Fund Advisors bought 913,372 shares in the last quarter and now controls 267,568,955 shares of the PFE stock, with the valuation hitting $11,679,384,886.
Similarly, Capital Research Management Co increased its Pfizer Inc. shares by +124.77% during the recently filed quarter. After buying 47,202,436 shares in the last quarter, the firm now controls 85,032,960 shares of Pfizer Inc. which are valued at $3,711,688,704. In the same vein, JPMorgan Investment Management I increased its Pfizer Inc. shares by during the most recent reported quarter. The firm bought 1,577,175 shares during the quarter which increased its stakes to 75,213,954 shares and is now valued at $3,283,089,092. Following these latest developments, around 0.06% of Pfizer Inc. stocks are owned by institutional investors and hedge funds.